
Review top news and interview highlights from the week ending April 29, 2022.
Review top news and interview highlights from the week ending April 29, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending April 15, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, joins CGTL to discuss ImmTOR, an immune tolerance platform that could ultimately enable gene therapy redosing in certain cases.
Review top news and interview highlights from the week ending April 15, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending April 8, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending April 1, 2022.
Positive interim results from a phase 3 study presented at AAD 2022 bolster recently published phase 2 data.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending March 25, 2022.
The professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Michael Singer, MD, PhD, cofounder and chief scientific officer of Cartesian Therapeutics, discussed the company’s lead candidate, Descartes-08.
Kinnari Patel, PharmD, president and chief operating officer of Rocket Pharmaceuticals, discussed Rocket Pharma’s programs.
Viral vectors have become the most common method for delivering gene therapy; however, pre-existing humoral immunogenicity can potentially render a gene therapy ineffective.
Review top news and interview highlights from the week ending March 18, 2022.
The draft guidance from the Center for Biologics Evaluation and Research outlines safety considerations throughout the clinical development program timeline.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The associate professor from UC San Diego discussed the ongoing phase ½ trial of CTNS-RD
The company is planning to initiate a phase 1 trial in the second half of 2022.
Review top news and interview highlights from the week ending March 11, 2022.
The director of research and development at AVROBIO discussed the molecular follow-up of cell therapies.